NO20074722L - Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter - Google Patents

Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter

Info

Publication number
NO20074722L
NO20074722L NO20074722A NO20074722A NO20074722L NO 20074722 L NO20074722 L NO 20074722L NO 20074722 A NO20074722 A NO 20074722A NO 20074722 A NO20074722 A NO 20074722A NO 20074722 L NO20074722 L NO 20074722L
Authority
NO
Norway
Prior art keywords
kinase inhibitor
egrr
growth factor
factor receptor
epidermal growth
Prior art date
Application number
NO20074722A
Other languages
English (en)
Norwegian (no)
Inventor
Lee Martin Greenberger
Charles M Zacharchuk
Susan E Quinn
Patricia Martins Harris
Ante Bill Lundberg
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20074722L publication Critical patent/NO20074722L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20074722A 2005-04-14 2007-09-17 Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter NO20074722L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67128705P 2005-04-14 2005-04-14
PCT/US2006/012877 WO2006113151A2 (fr) 2005-04-14 2006-04-07 Utilisation d'un inhibiteur kinase du recepteur du facteur de croissance epidermique (egfr) chez des patients resistant a la gefitinib

Publications (1)

Publication Number Publication Date
NO20074722L true NO20074722L (no) 2007-11-12

Family

ID=36791648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074722A NO20074722L (no) 2005-04-14 2007-09-17 Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter

Country Status (19)

Country Link
US (1) US20060235046A1 (fr)
EP (1) EP1871371A2 (fr)
JP (1) JP2008536847A (fr)
KR (1) KR20080002826A (fr)
CN (1) CN101160129A (fr)
AR (1) AR053357A1 (fr)
AU (1) AU2006236940A1 (fr)
BR (1) BRPI0610574A2 (fr)
CA (1) CA2646257A1 (fr)
CR (1) CR9415A (fr)
GT (1) GT200600146A (fr)
IL (1) IL186302A0 (fr)
MX (1) MX2007012662A (fr)
NO (1) NO20074722L (fr)
PE (1) PE20061396A1 (fr)
RU (1) RU2007134908A (fr)
TW (1) TW200718421A (fr)
WO (1) WO2006113151A2 (fr)
ZA (1) ZA200708755B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (fr) * 2005-11-04 2008-07-16 Wyeth Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) * 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
WO2010086382A1 (fr) * 2009-01-30 2010-08-05 Pronota N.V. Cible pour le traitement d'une insuffisance cardiaque aiguë
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
JP2013516422A (ja) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド タンパク質のリガンド−指向性共有的修飾
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2005018677A2 (fr) * 2003-08-01 2005-03-03 Wyeth Holdings Corporation Utilisation d'un melange d'un inhibiteur de la kinase du recepteur de facteur de croissance epidermique et d'agents cytotoxiques dans le traitement et l'inhibition de cancer
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
KR101313702B1 (ko) * 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물

Also Published As

Publication number Publication date
PE20061396A1 (es) 2007-01-12
ZA200708755B (en) 2008-10-29
GT200600146A (es) 2006-11-07
CR9415A (es) 2008-01-21
BRPI0610574A2 (pt) 2010-07-06
AU2006236940A1 (en) 2006-10-26
WO2006113151A3 (fr) 2007-01-11
IL186302A0 (en) 2008-08-07
MX2007012662A (es) 2008-04-04
CN101160129A (zh) 2008-04-09
KR20080002826A (ko) 2008-01-04
RU2007134908A (ru) 2009-05-20
CA2646257A1 (fr) 2006-10-26
TW200718421A (en) 2007-05-16
JP2008536847A (ja) 2008-09-11
EP1871371A2 (fr) 2008-01-02
WO2006113151A2 (fr) 2006-10-26
AR053357A1 (es) 2007-05-02
US20060235046A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2020093006A8 (fr) Méthodes de traitement du cancer chez des patients identifiés par biomarqueurs avec des inhibiteurs non covalents de la kinase cycline-dépendante 7 (cdk7)
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
TNSN08088A1 (en) Substituted benzimidazoles as kinase inhibitors
HUS1600033I1 (hu) Eljárás gefitinib rezisztens rák kezelésére
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
PT2420234E (pt) 1h-benzimidazole-4-carboxamidas substituídas com um carbono quaternário na posição 2 como inibidores de parp para uso no tratamento do cancro
EA201000341A1 (ru) 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
NO20080168L (no) Aminoquinolin- og aminoquinoazolinkinasemodulatorer
BRPI0815715A8 (pt) Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
NO20080161L (no) Aminopyrimidiner som kinasemodulatorer
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
EA200870454A1 (ru) Способ ингибирования c-kit киназы
ATE424208T1 (de) Proteinkinaseinhibitoren
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application